> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Viridian Stock Soars 8% After First Lumvoa Quarter Brings In $24.7 Million
- URL: https://www.bullished.co/viridian-stock-soars-8-after-first-lumvoa-quarter-brings-in-24-7-million-9abb669f/
- Published: 2026-11-04T14:52:34.000Z
- Updated: 2026-11-04T14:52:34.000Z
- Description: Shares added $228 million in value as Lumvoa's launch topped 100 patients by September's end.
- Author: Matteo Parrino
- Tags: Markets, VRDN, Industry: Healthcare

[Viridian Therapeutics](https://www.bullished.co/tag/vrdn/) shares climbed 7.99% to $27.16 in Wednesday trading, as of 9:51 a.m. ET, adding $228 million in market value after the company [reported](https://www.businesswire.com/news/home/20261104573611/en/Viridian-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Highlights-Recent-Business-Progress?ref=bullished.co) $24.7 million in net product revenue from Lumvoa, its first quarter selling the drug. The biotech, which develops medicines for serious and rare autoimmune diseases, was on pace for its biggest one-day gain since October 19, when it rose 9.3%.

## A launch ahead of expectations

Lumvoa treats thyroid eye disease, a rare autoimmune condition that inflames the tissue around the eye. It is Viridian's first commercial product. [More than 100 patients](https://www.benzinga.com/news/26/11/62863545/viridian-therapeutics-q3-2026-earnings-call-transcript?ref=bullished.co) were on therapy at the end of September, the company said.

CEO Steve Mahoney said on the [earnings call](https://www.benzinga.com/news/26/11/62863545/viridian-therapeutics-q3-2026-earnings-call-transcript?ref=bullished.co) that the launch "has exceeded expectations." Executives on the call declined to give market share or fourth-quarter guidance. About 30% of payers covered Lumvoa at the end of the third quarter, the company said on the call.

## Spending shifts from labs to sales

The [10-Q](https://www.sec.gov/Archives/edgar/data/1590750/000159075026000022/vrdn-20260930.htm?ref=bullished.co) shows lab spending dropped, with research and development at $70.1 million versus $86.3 million before. Sales and administrative costs climbed to $57.6 million, from $24.3 million.

Cash and marketable securities totaled [$955.2 million](https://www.businesswire.com/news/home/20261104573611/en/Viridian-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Highlights-Recent-Business-Progress?ref=bullished.co), which the company said should fund its plans through profitability.

## A stock still down for the year

Even with the jump, Viridian shares were down about 19% for the year as of Tuesday's close, while the S&P 500 was up about 11%. The stock had risen 30% over the previous month and sat 26% below its highest close of the past year, set on January 14.

Viridian is also developing elegrobart, an under-the-skin injection aimed at the same IGF-1R target. It plans to submit a license application to the FDA for it in the first quarter of 2027.

Viridian plans to file its FDA application for elegrobart in the first quarter of 2027.

### Sources

- [Viridian Therapeutics Q3 2026 Earnings Call Transcript](https://www.benzinga.com/news/26/11/62863545/viridian-therapeutics-q3-2026-earnings-call-transcript?ref=bullished.co) — benzinga.com
- [Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates](https://finance.yahoo.com/healthcare/articles/viridian-therapeutics-inc-vrdn-reports-125507951.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress](https://www.businesswire.com/news/home/20261104573611/en/Viridian-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Highlights-Recent-Business-Progress?ref=bullished.co) — businesswire.com
- [The company's filing (Viridian Therapeutics)](https://www.sec.gov/Archives/edgar/data/0001590750/000119312526446200/d176865d8k.htm?ref=bullished.co) — SEC filing
- [Viridian Therapeutics — Form 10-Q for the quarter ended 2026-09-30 (quarterly results)](https://www.sec.gov/Archives/edgar/data/1590750/000159075026000022/vrdn-20260930.htm?ref=bullished.co) — SEC EDGAR

### More on Viridian Therapeutics

- [Viridian's Lumvoa Brings In $24.7 Million In Its First Quarter On Sale As Net Loss Widens](https://www.bullished.co/viridians-lumvoa-brings-in-24-7-million-in-its-first-quarter-on-sale-as-net-loss-widens-f7d6d583/)

[All Viridian Therapeutics (VRDN) coverage →](https://www.bullished.co/tag/vrdn/)